.png?width=700&name=New-ATE-Logo2019%20(1).png)
Turning Biologic Innovation Into Commercial
Success: Boehringer Ingelheim’s Expertise
in Microbial Technology
Presenters:
Athelney Woolnough joined Boehringer Ingelheim in 2013 as a director of business development in contract manufacturing of biopharmaceuticals. She collaborated with a diverse clientele, from virtual biotech to large pharmaceutical companies, providing high-quality development and manufacturing solutions for recombinant protein and monoclonal antibody therapeutics. In 2017, Athelney's role expanded to director of key account management, overseeing a portfolio of strategic clients utilizing clinical and commercial services from Boehringer's Global Biopharmaceutical network. Before joining Boehringer Ingelheim, she held various positions in the contract manufacturing industry and began her career in genomic and molecular biology research. Athelney earned a bachelor's degree in cell and molecular biology, a master's degree in drug regulatory affairs, and a master's degree in business administration. She is passionate about the intersection of business and science in the biotech industry, as it offers an exciting opportunity to influence healthcare economics and patient-centricity.
Franz Schuster has been a part of Boehringer Ingelheim Austria (Boehringer Ingelheim RCV) for 30 years.With a robust background in quality control and quality assurance spanning 18 years and an additional eight years in CMC project management, his current role is that of a strategy implementation manager.
His journey with Boehringer Ingelheim began in 1993 when he took on the role of an analyst, responsible for the analytical testing of IPC and release material. Subsequently, he headed the HPLC lab and later led the team for chemical product testing. He was instrumental in implementing a supporting unit for project management of QC, QA, and stability support.
After several roles in quality, he transitioned to CMC project management. In this capacity, he led more than 12 different CMC projects, including microbial, mammalian, BI internal projects, and those for the contract manufacturing business.
Franz has been at the forefront of process improvements and has led both local and global projects related to business process excellence, strategic concepts, and infrastructure/logistics.
Cécile Brocard, a trained biochemist & molecular cell biologist, holds a degree in biochemistry and molecular cell biology from France and a doctoral degree in biochemistry from the prestigious University of Vienna, Austria. Currently, Cécile serves as the director of downstream development in the development operations Austria department at Boehringer Ingelheim Regional Center Vienna. In this pivotal role, she leads a talented team responsible for developing downstream processes for a wide range of recombinant proteins expressed in microbials. Their work is crucial for clinical supplies in phase I, II, and III trials, as well as overseeing tech transfer to production. Cécile’s team comprises two downstream development units and a non-GMP downstream pilot plant. Under her leadership, they are instrumental in driving technology programs and strategic initiatives within the organization. Cécile is dedicated to fostering innovation and improving process flows.
As a speaker and active participant in international conferences, Cécile aims to bring her knowledge and experience to the forefront, contributing to the advancement of biotechnology on a global scale. Her focus includes raising awareness about the complexity and variety of molecule formats expressed in microbials, while also highlighting the expertise of Boehringer Ingelheim in the realm of microbial process development technology and manufacturing.
